Crossroads Hospice Of Cleveland, Llc 9775 Rockside Road, Suite 270, Valley View, OH, 44125 | |
(216) 654-9300 |
News Archive
Preventing vascular congestion is an important mediator in heart failure, reports a study in the June issue of the Journal of Cardiac Failure, published by Elsevier.
Researchers from Mount Sinai School of Medicine will present several studies at the American Academy of Neurology Annual Meeting, including a potential new drug for the treatment of multiple sclerosis and surprising trends showing a reduction in the disease's severity. The meeting will take place April 10-17 in Toronto.
Sanofi-aventis U.S. announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Elitek (rasburicase) to be used for the initial management of plasma uric acid (PUA) levels in adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis syndrome (TLS) and subsequent elevations of plasma uric acid.
A team of Japanese scientists has used facial recognition technology to develop an automated system that can predict when patients in the intensive care unit are at high risk of unsafe behavior such as accidentally removing their breathing tube, with moderate (75%) accuracy.
› Verified 9 days ago
Name | Crossroads Hospice Of Cleveland, Llc |
---|---|
Location | 9775 Rockside Road, Suite 270, Valley View, Ohio |
Hospice ID | 361656 |
Category | Freestanding Hospice |
Ownership Type | Other |
Profit Type | OTHER |
Accreditation Provider | Community Health Accreditation Partner (CHAP) |
SSA county code | 170 |
News Archive
Preventing vascular congestion is an important mediator in heart failure, reports a study in the June issue of the Journal of Cardiac Failure, published by Elsevier.
Researchers from Mount Sinai School of Medicine will present several studies at the American Academy of Neurology Annual Meeting, including a potential new drug for the treatment of multiple sclerosis and surprising trends showing a reduction in the disease's severity. The meeting will take place April 10-17 in Toronto.
Sanofi-aventis U.S. announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Elitek (rasburicase) to be used for the initial management of plasma uric acid (PUA) levels in adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis syndrome (TLS) and subsequent elevations of plasma uric acid.
A team of Japanese scientists has used facial recognition technology to develop an automated system that can predict when patients in the intensive care unit are at high risk of unsafe behavior such as accidentally removing their breathing tube, with moderate (75%) accuracy.
› Verified 9 days ago
NPI Number | 1730329681 |
Organization Name | Crossroads Hospice Of Cleveland Llc |
Address | 9775 Rockside Rd Cleveland, Ohio, 44125 |
Phone Number | (216)654-9300 |
News Archive
Preventing vascular congestion is an important mediator in heart failure, reports a study in the June issue of the Journal of Cardiac Failure, published by Elsevier.
Researchers from Mount Sinai School of Medicine will present several studies at the American Academy of Neurology Annual Meeting, including a potential new drug for the treatment of multiple sclerosis and surprising trends showing a reduction in the disease's severity. The meeting will take place April 10-17 in Toronto.
Sanofi-aventis U.S. announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Elitek (rasburicase) to be used for the initial management of plasma uric acid (PUA) levels in adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis syndrome (TLS) and subsequent elevations of plasma uric acid.
A team of Japanese scientists has used facial recognition technology to develop an automated system that can predict when patients in the intensive care unit are at high risk of unsafe behavior such as accidentally removing their breathing tube, with moderate (75%) accuracy.
› Verified 9 days ago
Quality Measure | Provider Score | National Score |
---|---|---|
Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 93.7 | 98.3 |
Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 88.6 | 93.6 |
Patients who were checked for pain at the beginning of hospice care | 83.4 | 93.9 |
Patients who got a timely and thorough pain assessment when pain was identified as a problem | 56.3 | 77.7 |
Patients who were checked for shortness of breath at the beginning of hospice care | 85.0 | 97.3 |
Patients who got timely treatment for shortness of breath | 91.8 | 94.6 |
Patients taking opioid pain medication who were offered care for constipation | 82.1 | 93.3 |
News Archive
Preventing vascular congestion is an important mediator in heart failure, reports a study in the June issue of the Journal of Cardiac Failure, published by Elsevier.
Researchers from Mount Sinai School of Medicine will present several studies at the American Academy of Neurology Annual Meeting, including a potential new drug for the treatment of multiple sclerosis and surprising trends showing a reduction in the disease's severity. The meeting will take place April 10-17 in Toronto.
Sanofi-aventis U.S. announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Elitek (rasburicase) to be used for the initial management of plasma uric acid (PUA) levels in adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis syndrome (TLS) and subsequent elevations of plasma uric acid.
A team of Japanese scientists has used facial recognition technology to develop an automated system that can predict when patients in the intensive care unit are at high risk of unsafe behavior such as accidentally removing their breathing tube, with moderate (75%) accuracy.
› Verified 9 days ago
Home Health Aides | 48 |
Counselors | 8 |
Homemakers | 0.1 |
Licensed Practical or Vocational Nurses | 4 |
Medical Social Workers | 8 |
Physicians | 1.4 |
Registered Nurses | 43 |
Other Personnel | 44 |
Total Employees | 156.5 |
---|
News Archive
Preventing vascular congestion is an important mediator in heart failure, reports a study in the June issue of the Journal of Cardiac Failure, published by Elsevier.
Researchers from Mount Sinai School of Medicine will present several studies at the American Academy of Neurology Annual Meeting, including a potential new drug for the treatment of multiple sclerosis and surprising trends showing a reduction in the disease's severity. The meeting will take place April 10-17 in Toronto.
Sanofi-aventis U.S. announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Elitek (rasburicase) to be used for the initial management of plasma uric acid (PUA) levels in adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis syndrome (TLS) and subsequent elevations of plasma uric acid.
A team of Japanese scientists has used facial recognition technology to develop an automated system that can predict when patients in the intensive care unit are at high risk of unsafe behavior such as accidentally removing their breathing tube, with moderate (75%) accuracy.
› Verified 9 days ago
Others | 16 |
Total Volunteers | 16 |
---|
News Archive
Preventing vascular congestion is an important mediator in heart failure, reports a study in the June issue of the Journal of Cardiac Failure, published by Elsevier.
Researchers from Mount Sinai School of Medicine will present several studies at the American Academy of Neurology Annual Meeting, including a potential new drug for the treatment of multiple sclerosis and surprising trends showing a reduction in the disease's severity. The meeting will take place April 10-17 in Toronto.
Sanofi-aventis U.S. announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Elitek (rasburicase) to be used for the initial management of plasma uric acid (PUA) levels in adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis syndrome (TLS) and subsequent elevations of plasma uric acid.
A team of Japanese scientists has used facial recognition technology to develop an automated system that can predict when patients in the intensive care unit are at high risk of unsafe behavior such as accidentally removing their breathing tube, with moderate (75%) accuracy.
› Verified 9 days ago
Crossroads Hospice Of Cleveland, Llc Location: 9775 Rockside Road, Suite 270, Valley View, Ohio, 44125 Phone: (216) 654-9300 |